#USA #San Francisco #Hagens Berman #ARD-101 #Aardvark

Aardvark Therapeutics Faces Lawsuit for Securities Fraud

In a significant development for investors, Aardvark Therapeutics, Inc. (NASDAQ: AARD) is currently facing a class action lawsuit due to accusations of securities fraud. The leading law firm, Hagens Berman Sobol Shapiro LLP, has brought this lawsuit to attention, indicating that investors who acquired Aardvark's shares during its initial public offering (IPO) and subsequent offerings between February 2025 and May 2026 may have experienced financial losses as a result of misleading information provided by the company.

Understanding the Allegations

The lawsuit claims that Aardvark Therapeutics misled its investors regarding the safety of its lead product, ARD-101. This small-molecule therapy was developed to target bitter taste receptors for treating conditions such as hyperphagia in individuals with Prader-Willi Syndrome (PWS). However, the complaint suggests that crucial data regarding the drug's safety was not disclosed, which misinformed investors regarding the drug's efficacy and its overall development.

Key allegations specify that:

• - The safety profile of ARD-101 was significantly overstated by the company, potentially impacting its market value.
• - Unexpected cardiac observations, such as QRS prolongation during clinical trials, raised serious concerns regarding the drug's safety at higher doses, which were not disclosed to investors.

Significant Timeline of Events

The situation began to unravel on February 27, 2026, when Aardvark announced a voluntary pause in its Phase 3 HERO (Hunger Elimination or Reduction Objective) trial due to these cardiovascular safety concerns identified during healthy volunteer studies. Immediately following this announcement, investors reacted, leading to a staggering 56% drop in Aardvark's stock price, warning the market and raising questions about clinical prospects.

In another critical turn on May 14, 2026, the U.S. Food and Drug Administration (FDA) enacted a full clinical hold on Aardvark’s investigational new drug application for ARD-101. This action suspended ongoing studies under the IND (Investigational New Drug), including the HERO trial. The immediate result was a further 32% decline in the company's stock.

Hagens Berman's Investigation

Law firm Hagens Berman is conducting an extensive investigation into these allegations, focusing on whether Aardvark actively misled its investors about ARD-101’s safety and viability. Reed Kathrein, the partner managing the investigation, has indicated the seriousness of these claims, underscoring the firm’s commitment to holding companies accountable for misleading actions. The firm urges any investors affected by this event to actively participate in their legal rights concerning the ongoing suit.

Legal Recourse for Investors

Aardvark investors who experienced losses are encouraged to reach out to Hagens Berman promptly. As potential class members, interested parties can submit information to the firm until the lead plaintiff motion deadline set for October 13, 2026. This could include reporting specific losses incurred and the nature of their investments during the relevant periods.

The firm is also open to whistleblowers who may possess additional non-public information about Aardvark's operations and safety evaluations. These individuals can potentially benefit from the SEC Whistleblower program, which awards up to 30% of recovery made by the SEC due to original information provided.

About Hagens Berman

Hagens Berman is renowned for its significant role in securities litigation and corporate accountability. With a history of securing almost $2.9 billion in settlements for investors and consumers, the firm is regarded as one of the leading plaintiffs' rights law firms nationwide. Continued updates about the case and other corporate accountability issues can be found on the firm’s website or through their social media channels.

This news has raised eyebrows in the biopharmaceutical investment community, and many are now watching closely to see how Aardvark Therapeutics will respond to these grave allegations.